Today, a Director at Acelrx (NASDAQ: ACRX), Mark G. Edwards, bought shares of ACRX for $15.05K.
Following this transaction Mark G. Edwards’ holding in the company was increased by 3.42% to a total of $456.9K. In addition to Mark G. Edwards, one other ACRX executive reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Acelrx has an average volume of 1.15M.
Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $5.33, reflecting a -42.8% downside. 12 different firms, including Canaccord Genuity and Cantor Fitzgerald, currently also have a Buy rating on the stock.
The insider sentiment on Acelrx has been positive according to 16 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of acute pain. Its products include DSUVIA and ZALVISO. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.
Read More on ACRX:
